Incyte agreed to buy Vega Therapeutics’ Star subsidiary in a deal worth $1.25 billion upfront, with up to $750 million in sales milestones, to add the phase III von Willebrand disease asset VGA-039 to its hematology portfolio. The transaction is expected to close in the third quarter of 2026, subject to conditions, after both boards approved.